Frontotemporal Dementia Pipeline Insight

DelveInsight’s, “Frontotemporal Dementia - Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Frontotemporal Dementia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Frontotemporal Dementia Understanding

Frontotemporal Dementia: Overview

Frontotemporal dementia is an uncommon type of dementia that causes problems with behaviour and language. Dementia is the name for problems with mental abilities caused by gradual changes and damage in the brain. Frontotemporal dementia affects the front and sides of the brain (the frontal and temporal lobes).Dementia mostly affects people over 65, but frontotemporal dementia tends to start at a younger age. Most cases are diagnosed in people aged 45-65, although it can also affect younger or older people. Like other types of dementia, frontotemporal dementia tends to develop slowly and get gradually worse over several years. Signs of frontotemporal dementia can include: personality and behaviour changes – acting inappropriately or impulsively, appearing selfish or unsympathetic, neglecting personal hygiene, overeating, or loss of motivation, language problems – speaking slowly, struggling to make the right sounds when saying a word, getting words in the wrong order, or using words incorrectly, problems with mental abilities – getting distracted easily, struggling with planning and organisation. Signs of frontotemporal dementia can include: personality and behaviour changes – acting inappropriately or impulsively, appearing selfish or unsympathetic, neglecting personal hygiene, overeating, or loss of motivation, language problems – speaking slowly, struggling to make the right sounds when saying a word, getting words in the wrong order, or using words incorrectly, problems with mental abilities – getting distracted easily, struggling with planning and organisation. People with the condition can become socially isolated as the illness progresses. They may not want to spend time in the company of others, or may behave in rude or insulting ways. Frontotemporal dementia is caused by clumps of abnormal protein forming inside brain cells. These are thought to damage the cells and stop them working properly. The proteins mainly build up in the frontal and temporal lobes of the brain at the front and sides. These are important for controlling language, behaviour, and the ability to plan and organise.

 

“Frontotemporal Dementia- Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Frontotemporal Dementia pipeline landscape is provided which includes the disease overview and Frontotemporal Dementia treatment guidelines. The assessment part of the report embraces, in depth Frontotemporal Dementia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Frontotemporal Dementia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Frontotemporal Dementia R&D. The therapies under development are focused on novel approaches to treat/improve Frontotemporal Dementia. 

Frontotemporal Dementia Emerging Drugs Chapters

This segment of the Frontotemporal Dementia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Frontotemporal Dementia Emerging Drugs

 

PR 006 : Prevail Therapeutics

PR006 is being developed as a potentially disease-modifying, single-dose gene therapy for patients with frontotemporal dementia with GRN mutations (FTD-GRN). PR006 is designed to slow or stop disease progression in FTD-GRN patients by increasing progranulin levels via delivery of a healthy GRN gene into the central nervous system (CNS). PR006 is administered by injection into the cisterna magna, using the well-studied viral vector AAV9.The U.S. FDA has granted Orphan Drug designation for the treatment of FTD and Fast Track designation for the treatment of FTD-GRN. The European Commission has granted orphan designation for PR006 for the treatment of FTD.PR006 is currently being studied in our PROCLAIM trial, a Phase 1/2 clinical trial of PR006 for the treatment of patients with FTD-GRN.

 

Latozinemab : Alector

AL001 modulates progranulin (PGRN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. We are initially developing AL001 for frontotemporal dementia (FTD) with progranulin mutation (FTD-GRN). The global INFRONT-3 Phase 3 clinical trial is currently enrolling both at-risk and symptomatic participants with FTD-GRN.AL001 is being developed in collaboration with GSK.

 

PBFT 02 : Passage Bio

Passage Bio, gene therapy product candidate, PBFT02, an AAV1 viral vector to deliver a modified DNA encoding the granulin gene (GRN) to a patient’s cells. The vector will be delivered directly to the cerebrospinal fluid by a single injection to the cisterna magna (ICM injection). The goal of this vector and delivery approach is to provide higher-than-normal levels of the progranulin protein (PGRN) to the CNS to overcome the progranulin deficiency in GRN gene mutation carriers. Currently the product is in Phase I/II for the treatment of Frontotemporal Dementia.

 

WVE 004 : WaVe life Sciences

WVE-004 is an investigational variant-selective silencing candidate designed to selectively target the transcript variants containing a hexanucleotide repeat expansion (G4C2) in the C9orf72 gene, while sparing the healthy C9orf72 protein. G4C2 expansions are one of the most common genetic causes of the sporadic and inherited forms of ALS and FTD.

 

EXO 050 : Coya Therapeutics

EXO 050, is the lead drug candidate of Coya Therapeutics for the treatment of FTD.Currently, the drug is in Pre-Clinical stage of development for the treatment of FTD.  

Further product details are provided in the report……..

Frontotemporal Dementia: Therapeutic Assessment

This segment of the report provides insights about the different Frontotemporal Dementia drugs segregated based on following parameters that define the scope of the report, such as:

 

Major Players in Frontotemporal Dementia

There are approx. 20+ key companies which are developing the therapies for Frontotemporal Dementia. The companies which have their Frontotemporal Dementia drug candidates in the most advanced stage, i.e. phase III include, Alector.

Phases
DelveInsight’s report covers around 20+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of 
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Route of Administration

Frontotemporal Dementia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

  • Intra-articular
  • Intraocular
  • Intrathecal 
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Molecule Type

Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Frontotemporal Dementia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Frontotemporal Dementia therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Frontotemporal Dementia drugs.

Frontotemporal Dementia Report Insights

  • Frontotemporal Dementia Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Frontotemporal Dementia Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Frontotemporal Dementia drugs?
  • How many Frontotemporal Dementia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Frontotemporal Dementia?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Frontotemporal Dementia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Frontotemporal Dementia and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Frontotemporal Dementia: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Frontotemporal Dementia– DelveInsight’s Analytical Perspective

Late Stage Products (Pre-Registration)

  • Comparative Analysis

Drug name : Company name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Last Stage Products (Phase III)

  • Comparative Analysis

Latozinemab : Alector

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (PhaseI/ II)

  • Comparative Analysis

PR 006 : Prevail Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

EXO 050 : Coya Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Frontotemporal Dementia Key Companies

Frontotemporal Dementia Key Products

Frontotemporal Dementia - Unmet Needs

Frontotemporal Dementia - Market Drivers and Barriers

Frontotemporal Dementia - Future Perspectives and Conclusion

Frontotemporal Dementia Analyst Views

Frontotemporal Dementia Key Companies

Appendix

List of Table

Table 1: Total Products for Frontotemporal Dementia

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Frontotemporal Dementia

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products   

• Alector
•  Prevail Therapeutics
•  Passage Bio, Inc.
•  TauRx Pharmaceuticals
•  Wave Life Sciences Ltd.
•  CAMP4 Therapeutics
•  Coya Therapeutics
• Alkermes
• DEEP GENOMICS
•  Sangamo Therapeutics
•  LOCANABIO
•  Arkuda Therapeutics
•  AZTherapies
•  Yumanity
•  Autifony Therapeutics
•  Prothena

 

 

Forward to Friend

Need A Quote